Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 8Recruiting 5Terminated 4Unknown 3Not yet recruiting 2Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

pembrolizumab 439Carboplatin 323Nivolumab 291Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 254Paclitaxel 249Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 169atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Radiosurgery 114Oxaliplatin 114Pemetrexed 113Etoposide 111Fluorouracil 110venetoclax 108fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Biological Products × Clear all
NCT01430390 2025-06-11

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
19 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡